Broad applicability of the Goldspire™ platform for the treatment of solid tumors

• Published in: Clinical immunology (Orlando, Fla.) Fla.), 2024-11, Vol.268, p.110373, Article 110373
• Main Authors: Zilberberg, Jenny, Uhl, Christopher, Scott, Charles B., Andrews, David W., Exley, Mark A.
• Format: Article
• Language: English
• Subjects: Animals; cancer vaccine; Check point inhibitor; Humans; Immunogenic cell death; Immunotherapy - methods; Mice; Neoplasms - immunology; Neoplasms - therapy; Oligonucleotides, Antisense - therapeutic use; Precision Medicine - methods; Receptor, IGF Type 1 - immunology
• ISSN: 1521-6616; 1521-7035; 1521-7035
• DOI: 10.1016/j.clim.2024.110373

Goldspire™ is a personalized immunotherapy platform that combines whole tumor-derived cells with antisense oligonucleotide (IMV-001) against Insulin-Like Growth Factor-1 Receptor (IGF-1R) in biodiffusion chambers (BDCs; 0.1 μm pore). BDCs are exposed to 5–6 Gy and implanted at abdominal sites for ∼48 h to deliver an antigenic payload and immunostimulatory factors to train the immune system. Lead product IGV-001 was evaluated in newly diagnosed glioblastoma (ndGBM) patients in Phase 1a and 1b trials (NCT02507583). A Phase 2b study (NCT04485949) recently completed enrollment. Preventative treatment with tumor-specific products manufactured with Goldspire limited tumor progression and extended overall survival in mice challenged with bladder, pancreatic, ovarian, colorectal, or renal carcinomas. The benefit of this immunotherapy was enhanced with anti-PD-1; combination treatment was superior to either monotherapy in orthotopic GBM and melanoma models. Lastly, Goldspire elicited immune T cell activation and memory phenotypes against patient-derived endometrial tumor-derived products in co-cultures with matching immune cells. [Display omitted] •Goldspire™ platform enables durable systemic immunity in multiple cancer models and induces patient antitumor immune responses in vitro.•Mice receiving urothelial, pancreatic or ovarian murine products had significantly longer survival after respective tumor challenge vs. controls.•Mice receiving colorectal or renal murine products had relative resistance to subcutaneous tumor challenge vs. controls.•Mice receiving glioblastoma or melanoma products + anti-PD1 mAb had significantly longer survival and durable tumor control vs. controls.•Patient endometrial product induced dendritic and T cell activation and memory phenotypes in co-cultures with matched blood cells.